Lilly Gets Second Interchangeable Insulin Glargine In US
Further FDA Approval For Rezvoglar Biosimilar Adds Second Interchangeable Option
Executive Summary
Eli Lilly has been granted an interchangeability designation by the US FDA for its Rezvoglar insulin glargine biosimilar, matching the designation previously granted for Viatris’ Semglee.
You may also be interested in...
From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
Provisionally Interchangeable? FDA Weighs ‘Requirements’ For Pfizer’s Adalimumab
Pfizer has responded to Generics Bulletin’s queries regarding its bid to win an interchangeability designation for its Abrilada (adalimumab-afzb) biosimilar to AbbVie’s Humira reference product.